Company Overview and News

 
Institutional investors veto reappointment of yet another conglomerate head

2018-10-14 thehindubusinessline
PALAK SHAH For the second time this year, some large institutional shareholders have vetoed the reappointment of a top-level corporate executive as the chairman of a group’s flagship company.
HNDNF HINDALCO CLNDY 533278 COALINDIA 500440

 
D-Street Buzz: Nifty auto outperforms with Ashok Leyland up 5%; HPCL jumps 4%, realty stocks gains

2018-10-12 moneycontrol
Yesterday was the day we want to forget and focus on today as the Indian stock market is witnessing some robust gains with the Nifty50 jumping 157 points, trading at 10,391 while the Sensex has zoomed over 460 points at 34,462.
IOC 500325 533096 532832 533137 DEN GAILF EICHERMOT RLNIY ASHOKLEY TVSMOTOR UNITDSPR 530965 517334 AKLD JSWSTEEL 500182 532432 TATASTEEL TATLY GAILY UQNTY AKLS IBREALEST HINDCOPPER GODREJIND 533150 500228 RELIANCE 533273 533155 JUBLFOOD 505200 532343 MOZTY 500470 RIGD JBLWY HEROMOTOCO 500477 ECQRY HINDALCO 513599 HNDNF OBZIY GODREJPROP TTST OBEROIRLTY MOTHERSUMI HRTQY ADANIPOWER 500164 500440

 
Nifty metal underperforms, tanks over 4% as Tata Steel, JSPL, Hindalco fall 4-5%

2018-10-11 moneycontrol
It is absolute carnage on Dalal Street as the benchmark indices have tanked over 2.5 percent. Nifty50 has tanked 275 points and is trading at 10,184 while the Sensex has crashed 875 points and is trading at 33,885 mark.
HNDNF 500470 HINDALCO TTST TATASTEEL TATLY 500440

2
India’s aluminum producers increase sales to Japan amid industry shake-up

2018-10-09 japantimes.co.jp
Indian aluminum producers including Hindalco Industries and Vedanta Ltd. are boosting sales to Japan as U.S. sanctions against Russia’s Rusal and import tariffs shake up traditional supply routes.
HNDNF RTPPF RIO HINDALCO RIO RIO RUALF RTNTF 500440 VEDL

2
India’s aluminium makers win Japan sales in market shake-up

2018-10-09 thehindubusinessline
India's export of aluminium ingot to Japan has doubled in the first eight months of 2018 (file photo)
HNDNF RTPPF RIO HINDALCO RIO RIO RUALF RTNTF 500440 VEDL

2
Indian aluminium makers win Japan sales in market shake-up

2018-10-09 livemint
Tokyo/New Delhi: Indian aluminium makers including Hindalco Industries and Vedanta Ltd are boosting sales to Japan as U.S. sanctions against Russia’s Rusal and import tariffs shake up traditional supply routes. India’s product has generally not been regarded as high enough quality by Japan’s demanding buyers, who have preferred top-tier producers like Rio Tinto , Alcoa and South32 as well as United Company Rusal.
HNDNF RTPPF RIO HINDALCO RIO RIO RUALF RTNTF 500440 VEDL

2
India’s aluminium makers win Japan sales

2018-10-09 thestar.com.my
Playing safe: Making aluminium ingots at the foundry shop of the Rusal Krasnoyarsk aluminium smelter in the Siberian city of Krasnoyarsk. Consumers prefer multiple suppliers to ensure some security of supply. — Reuters
HNDNF RTPPF RIO HINDALCO RIO RIO RUALF RTNTF 500440 VEDL

 
Aluminium firms suffer sharp share price drop on global cues

2018-10-08 financialexpress
Share prices of domestic aluminium companies fell sharply on Monday dragging the BSE metal index, which closed down 3.18%, according to Bloomberg data. The fall was in line with the negative stock reactions globally, analysts said.
532234 HNDNF NHYKF HINDALCO NHYDY NHY 500440 NATIONALUM

 
Metal stocks fall with Vedanta plunging 11%, hits new 52-week low; Hindalco, NALCO shed 5-9%

2018-10-08 moneycontrol
The Indian stock market has once again plunged this afternoon with the Nifty50 shedding 114 points, trading at 10,202 while the Sensex has lost 391 points at 33,985.
HINDCOPPER HINDALCO 500228 513599 HNDZY 533278 JSWSTEEL HNDNF 500470 TTST TATASTEEL TATLY CLNDY COALINDIA 500440 500188 HINDZINC

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...